This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

Bonnie L. Bassler net worth and biography

Bonnie Bassler Biography and Net Worth

Director of Regeneron Pharmaceuticals

Bonnie L. Bassler, PhD, joined the board in 2016. She is currently the Chair of the Department of Molecular Biology and the Squibb Professor in Molecular Biology at Princeton University, and a Howard Hughes Medical Institute Investigator. Dr. Bassler has previously served as the President of the American Society for Microbiology, as well as on the boards for the American Association for the Advancement of Science, the National Science Foundation and the American Academy of Microbiology. She has been elected to the National Academy of Sciences, the American Academy of Arts and Sciences, the Royal Society and the American Philosophical Society and has received many scientific honors, including a MacArthur Foundation Fellowship, the Lounsbery Award and the Shaw Prize for Life Science and Medicine. Dr. Bassler received her BSc from the University of California, Davis, and her PhD in Biochemistry from Johns Hopkins University. She served as a Postdoctoral Fellow and Research Scientist at the Agouron Institute in La Jolla, CA, before becoming a faculty member at Princeton University. Dr. Bassler served as a director of Sanofi from November 2014 to July 2016 and currently serves on the board of directors of Kaleido Biosciences, Inc.

What is Bonnie L. Bassler's net worth?: The estimated net worth of Bonnie L. Bassler is at least $1.05 million as of June 24th, 2024. Ms. Bassler owns 1,382 shares of Regeneron Pharmaceuticals stock worth more than $1,053,554 as of December 3rd. This net worth evaluation does not reflect any other investments that Ms. Bassler may own. Learn More about Bonnie L. Bassler's net worth.
How do I contact Bonnie L. Bassler?: The corporate mailing address for Ms. Bassler and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on Bonnie L. Bassler's contact information.
Has Bonnie L. Bassler been buying or selling shares of Regeneron Pharmaceuticals?: Bonnie L. Bassler has not been actively trading shares of Regeneron Pharmaceuticals during the past quarter. Most recently, Bonnie L. Bassler sold 756 shares of the business's stock in a transaction on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a transaction totalling $802,872.00. Following the completion of the sale, the director now directly owns 1,382 shares of the company's stock, valued at $1,467,684. Learn More on Bonnie L. Bassler's trading history.
Who are Regeneron Pharmaceuticals' active insiders?: Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Regeneron Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 27 times. They sold a total of 107,995 shares worth more than $105,556,492.64. The most recent insider tranaction occured on August, 28th when CFO Christopher R Fenimore sold 5,680 shares worth more than $6,846,274.40. Insiders at Regeneron Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.
Information on this page was last updated on 8/28/2024.

Bonnie L. Bassler Insider Trading History at Regeneron Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/24/2024	Sell	756	$1,062.00	$802,872.00	1,382
6/5/2024	Sell	827	$1,011.00	$836,097.00	1,382
2/26/2024	Sell	854	$979.25	$836,279.50	1,382
1/30/2024	Sell	827	$959.00	$793,093.00	1,382
8/21/2023	Sell	853	$829.00	$707,137.00	1,247
8/10/2023	Sell	853	$789.00	$673,017.00	1,247
3/24/2023	Sell	1,240	$818.00	$1,014,320.00	1,247
2/3/2023	Sell	1,021	$779.00	$795,359.00	1,247
12/8/2022	Sell	218	$779.00	$169,822.00	1,082
9/9/2022	Sell	609	$741.00	$451,269.00	1,082
4/7/2022	Sell	1,240	$725.00	$899,000.00	1,082
8/5/2021	Sell	2,559	$600.00	$1,535,400.00	3,450
6/19/2020	Sell	2,559	$630.02	$1,612,221.18	3,202
6/5/2020	Sell	2,559	$600.00	$1,535,400.00	3,202

Bonnie L. Bassler Buying and Selling Activity at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Today's Range

Now: $752.62

$752.36

$770.00

50 Day Range

MA: $905.64

$738.00

$1,091.98

2 Week Range

Now: $752.62

$735.95

$1,211.20

Volume

178,127 shs

Average Volume

542,892 shs

Market Capitalization

$82.71 billion

P/E Ratio

18.62

Dividend Yield

N/A

Beta

0.08

Musk’s new company could top a trillion?

From Paradigm Press | Ad

The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.

Click here to see the details because there’s not much time to prepare.